Mifepristone for Patients With Endometrial Cancer and LGESS
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To determine the antitumor activity of Mifepristone (RU-486) in patients with advanced
or recurrent endometrioid adenocarcinoma or low grade endometrial stromal sarcoma
(LGESS).
2. To evaluate the quantitative and qualitative toxicities of Mifepristone in this patient
population.
3. To evaluate at a tissue level the effect of Mifepristone on estrogen and progesterone
receptors post treatment and to evaluate other markers that may reflect effects of
Mifepristone on cancer cell growth.
4. To evaluate the effect of the agent and dosing schedule on the patient's quality of
life.